GGHC
VRNA

Gilder Gagnon Howe & Co’s Verona Pharma VRNA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-365,258
Closed -$34.5M – 263
2025
Q2 		$34.5M Buy
365,258
+305,547
+512% +$22.6M 0.37% 69
2025
Q1 		$3.79M Buy
+59,711
New +$3.57M 0.05% 146

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gilder Gagnon Howe & Co's VRNA Position: Q3 2025 in Review

Gilder Gagnon Howe & Co sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 365,258 shares — an estimated $34.5M sold.

Gilder Gagnon Howe & Co first reported a position in VRNA in Q1 2025 and held it in 2 quarters. The position peaked at $34.5M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Gilder Gagnon Howe & Co reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 365,258 Verona Pharma shares in Q3 2025, an estimated $34.5M.
  • Gilder Gagnon Howe & Co first reported a position in Verona Pharma in Q1 2025 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Verona Pharma position peaked at $34.5M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2025, filed 14 Nov 2025.